Glaukos Corporation $GKOS Shares Purchased by Bessemer Group Inc.

Bessemer Group Inc. grew its position in shares of Glaukos Corporation (NYSE:GKOS) by 2,270.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,542 shares of the medical instruments supplier’s stock after purchasing an additional 6,266 shares during the period. Bessemer Group Inc.’s holdings in Glaukos were worth $675,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. First Horizon Advisors Inc. boosted its stake in shares of Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 159 shares during the last quarter. Park Place Capital Corp boosted its stake in shares of Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 162 shares during the last quarter. AlphaQuest LLC boosted its stake in shares of Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 633 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in shares of Glaukos during the 1st quarter worth about $141,000. Finally, Revisor Wealth Management LLC acquired a new stake in shares of Glaukos during the 2nd quarter worth about $204,000. 99.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on GKOS shares. UBS Group raised their price target on shares of Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. Citigroup raised their price target on shares of Glaukos from $110.00 to $113.00 and gave the stock a “buy” rating in a research note on Thursday. Mizuho set a $130.00 target price on shares of Glaukos in a research report on Thursday, July 31st. William Blair raised shares of Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. Finally, The Goldman Sachs Group assumed coverage on shares of Glaukos in a research report on Wednesday, October 1st. They issued a “buy” rating and a $103.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and an average price target of $118.62.

Glaukos Trading Up 0.6%

GKOS stock opened at $88.29 on Friday. The company has a market cap of $5.06 billion, a price-to-earnings ratio of -57.33 and a beta of 0.76. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $85.43 and a 200-day simple moving average of $91.52. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $163.71.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. The business had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. Glaukos had a negative return on equity of 7.53% and a negative net margin of 18.65%.The business’s revenue for the quarter was up 38.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.28) EPS. Glaukos has set its FY 2025 guidance at EPS. On average, equities research analysts expect that Glaukos Corporation will post -1.08 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.